Stantec Inc. (TSE:STN – Get Free Report) (NYSE:STN) Director Vito Culmone acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was acquired at an average price of C$121.49 per share, for a total transaction of C$485,960.00.
Stantec Price Performance
Stantec stock traded down C$0.53 during trading on Wednesday, reaching C$120.25. The company had a trading volume of 336,469 shares, compared to its average volume of 262,909. The firm has a market capitalization of C$13.72 billion, a PE ratio of 39.73, a price-to-earnings-growth ratio of 1.46 and a beta of 0.82. The firm’s 50-day simple moving average is C$113.40 and its 200 day simple moving average is C$113.29. The company has a debt-to-equity ratio of 80.74, a quick ratio of 1.46 and a current ratio of 1.39. Stantec Inc. has a 1-year low of C$96.31 and a 1-year high of C$122.83.
Stantec Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.70%. Stantec’s dividend payout ratio is currently 27.63%.
Analyst Ratings Changes
View Our Latest Stock Report on Stantec
About Stantec
Stantec Inc provides professional services in the areas of infrastructure and facilities to the public and private sectors in Canada, the United States, and internationally. It offers evaluation, planning, and designing infrastructure solutions; solutions for sustainable water resources, planning, management, and infrastructure; environmental services; integrated architecture, engineering, interior design, and planning solutions for buildings; and energy and resources solutions.
Featured Stories
- Five stocks we like better than Stantec
- Consumer Discretionary Stocks Explained
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What Investors Need to Know to Beat the Market
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What is Insider Trading? What You Can Learn from Insider Trading
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Stantec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stantec and related companies with MarketBeat.com's FREE daily email newsletter.